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Abstract
Introduction This population-based study aims to assess 
prognosis of prostate cancer diagnosed with prostate-spe-
cifi c antigen (PSA) levels <4 ng/ml in routine care. 
Materials and methods We compared prostate cancer pa-
tients with low PSA values (n=59) with other prostate can-
cer patients (n=1330) by logistic regression and the Cox 
model using data from the Geneva Cancer Registry. 
Results Patients with low PSA values more frequently had 
early-stage and well differentiated tumours. Nevertheless, 
35% presented with aggressive tumour characteristics or 
metastases. After adjustment for other prognostic factors, 
prostate cancer-specific mortality was similar for both 
groups (hazard ratio: 1.1; 95%CI: 0.6–2.2). 
Conclusion We conclude that cancer with low PSA values 
at diagnosis is not indolent. 
Keywords Prostate cancer · Prostate-specifi c antigen · 
Tumour characteristics · Survival · Mortality
Introduction
Prostate-specifi c antigen (PSA) screening is widely used in 
North America and Europe. Health professionals in Geneva 
follow international guidelines, setting the threshold for 
biopsy referral at PSA ≥4 ng/ml [1]. Unless there is clinical 
suspicion (abnormal rectal examination), no further inves-
tigations are recommended for men presenting with PSA 
values <4 ng/ml. 
Prostate cancer in men with PSA levels <4.0 ng/ml is 
not unusual when systematically investigated. The reported 
prevalence of biopsy-confi rmed prostate cancer discovered 
in men presenting with “normal PSA” values range from 
approximately 2 to 26% depending on the threshold of 
PSA value considered [2–8]. However, in routine care these 
cancers are less frequent as they are only discovered fortu-
itously during endoscopic resection for prostate hyperpla-
sia or following additional investigations in case of clinical 
suspicion. Recent results from the Rotterdam section of the 
European randomised study of screening for prostate can-
cer showed a 2% detection rate of cancer among men with 
PSA <4 ng/ml referred for sextant biopsies after abnormal 
digital or ultrasound rectal examination [9]. In a Swedish 
population-based cohort study, prostate cancer diagnosed 
with PSA <4 ng/ml represented only 6% of all prostate 
cancers diagnosed in routine care [10].
Pathological characteristics and the impact of cancer diag-
nosed with low PSA values are not well known. Few studies 
have raised these specifi c questions by reporting on both tu-
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mour characteristics and prognosis among patients with PSA 
levels <4 ng/ml at diagnosis, showing contradictory results 
[11–23]. Some of the studies reported that tumours diagnosed 
at low PSA levels have better prognostic characteristics [2, 
12, 13, 16–18, 20–23], while other studies reported they had 
similar characteristics to other prostate tumours [8, 14, 19].
Most studies were limited to operated or irradiated 
patients with localised prostate cancer [11–15, 17, 23] or 
used biological failure to evaluate prognosis (increasing 
post-treatment PSA level), non-pertinent for tumours with 
low PSA production [11, 13, 14, 17, 18, 23].
To our knowledge, no previous studies have used pop-
ulation-based data to evaluate occurrence, characteristics 
and mortality of prostate cancer among patients with low 
PSA values in routine care. This is the aim of our study. 
Patients and methods
We used data from the population-based Geneva cancer 
registry, which records all incident cancer cases occurring 
in the canton (approximately 435,000 inhabitants). The 
registry collects information from various sources and is 
considered exhaustive, as attested by its low percentage 
(<2%) of patients recorded from death certifi cates only. 
All hospitals, pathology laboratories and practitioners are 
requested to report every cancer case. Registrars system-
atically abstract data from medical and laboratory fi les. 
Physicians regularly receive questionnaires to secure miss-
ing clinical and therapeutic data. Death certifi cates are con-
sulted systematically.
Recorded data include sociodemographic information, 
method of discovery, type of confi rmation, tumour histol-
ogy and grade (coded according to the International Clas-
sifi cation of Diseases for Oncology) [24], stage of disease 
at diagnosis, treatment during the fi rst six months after 
diagnosis, survival status and cause of death. 
The cancer registry regularly assesses survival, taking 
as reference date the date of confi rmation of diagnosis or 
the date of hospitalisation (if it preceded the diagnosis and 
was related to the disease). In addition to passive follow-
up (standard examination of death certifi cates and hospital 
records), active follow-up is performed yearly using the 
fi les of the Cantonal Population Offi ce in charge of the reg-
istration of the resident population. Cause of death is taken 
from clinical records and coded according to the World 
Health Organization’s classifi cation.
Between 1989 and 2000, 2267 men were diagnosed 
with invasive prostate cancer among the resident popula-
tion. We excluded patients with previous or synchronous in-
vasive cancer (except non-melanoma skin cancer) (n=224), 
patients with cancer discovered at death (n=11), unknown 
stage at diagnosis (n=461) and unknown PSA value at di-
agnosis (n=353). The study fi nally included 1383 patients. 
Tumour stage was based on the TNM classification 
system. We used pathological stage or, when absent, clini-
cal stage. Stage was classifi ed as T1 (clinically inapparent 
tumour not palpable or visible by imaging), T2 (tumour 
confi ned within the prostate), T3 (tumour extends through 
the prostate capsule with or without invasion of the seminal 
vesicles), T4 (tumour is fi xed or invades adjacent struc-
tures) or M1 (distant metastasis). Lymph node invasion was 
classifi ed as negative, positive or unknown [25].
Differentiation was classifi ed as Grade 1 (well differen-
tiated: Gleason 2–4), Grade 2 (moderately differentiated: 
Gleason 5–6), Grade 3–4 (poorly differentiated, undiffer-
entiated: Gleason 7–10) or unknown [25].
We considered all treatments given during the fi rst six 
months after prostate cancer diagnosis. Surgical treatment 
included radical, retropubic or perineal prostatectomy. 
We could not distinguish between chemical and hormonal 
castration. Radiotherapy consisted in external radiotherapy. 
Brachytherapy was not administered during the study pe-
riod. 
Statistical analysis
We used a case-control approach to compare patient and 
tumour characteristics between patients diagnosed with low 
PSA values (PSA <4 ng/ml) vs. elevated PSA values (PSA 
≥4 ng/ml). To identify sociodemographic and pathological 
characteristics clinically linked to PSA value at diagnosis 
we used unconditional logistic regression analyses.
Prostate cancer-specifi c survival was estimated by the 
actuarial method (intervals in days and standard error ac-
cording to Greenwood) [26]. To establish if low PSA level 
was independently linked to prognosis, we compared the 
risk of prostate cancer-specifi c mortality between the two 
groups using Cox proportional hazards analysis adjusted 
for other prognostic factors. All analyses were done with 
SPSS software (Version 14; SPSS Inc, Chicago, IL, USA).
Results
Only 53 (3.8%) prostate cancer patients had PSA values 
<4 ng/ml at diagnosis. Mean age of patients was 71 years 
(range 55–92) in the <4 ng/ml group and 70 years (range 
44–97) in the ≥4 ng/ml PSA group. 
Table 1 lists patient and tumour characteristics accord-
ing to PSA level at diagnosis. Crude logistic regressions 
showed that patients with low PSA levels were more often 
diagnosed in public care (p<0.001) and that the majority of 
patients (51%) had fortuitous discovery, usually following 
pathological fi ndings of prostate cancer after endoscopic 
prostate surgery. Furthermore, patients with low PSA lev-
els more often had earlier stage at diagnosis ((p<0.001) and 
less aggressive tumours ((p<0.010). The proportion of well 
differentiated tumours was 34% in patients with low PSA 
values and 12% among patients with elevated PSA values. 
However, six (11%) of the 53 patients presenting with low 
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PSA values at diagnosis had metastatic disease. All six had 
poorly differentiated tumours. Table 2 shows treatments 
delivered to patients according to their PSA values. Pa-
tients with low PSA values were more frequently managed 
with watchful waiting than patients with higher PSA levels 
(49% vs. 24%, (p<0.01).
Table 1 Patient and tumour characteristics and associated odds ratio for low PSA level at diagnosis
 PSA <4 ng/ml PSA ≥4 ng/ml Crude odds ratio
 N=53 N=1330 
 Cases Controls 
Age    
 <60 years 5 (9%) 182 (14%) 1a
 60–69 years 17 (32%) 511 (38%) 1.2 (0.4–3.3)
 70–79 years 20 (38%) 409 (31%) 1.8 (0.7–4.8)
 ≥80 years 11 (21%) 228 (17%) 1.8 (0.6–5.1)
Country of birth   
 Switzerland 34 (64%) 888 (67%) 1a
 Mediterranean 11 (21%) 233 (18%) 1.2 (0.6–2.5)
 Other 8 (15%) 209 (16%) 1.0 (0.5–2.2)
Civil status   
 Married 39 (74%) 1008 (76%) 1a
 Widowed 5 (9%) 146 (17%) 0.9 (0.3–2.3)
 Divorced 7 (13%) 106 (8%) 1.7 (0.7–3.9)
 Single 2 (4%) 70 (5%) 0.7 (0.2–3.1)
Social class   
 High  12 (23%) 360 (27%) 1a
 Middle  22 (42%) 567 (43%) 1.2 (0.6–2.4)
 Low 18 (34%) 376 (28%) 1.4 (0.7–3.0)
 Unknown 1 (2%) 27 (2%) 1.1 (0.1–8.9)
Period of diagnosis   
 1989–1991 11 (21%) 160 (12%) 1a
 1992–1994 10 (19%) 245 (18%) 0.6 (0.2–1.4)
 1995–1997 15 (28%) 418 (31%) 0.5 (0.2–1.2)
 1998–2000 17 (32%) 507 (38%) 0.5 (0.2–1.1)
Method of discovery   
 Symptoms 19 (36%) 542 (41%) 1a
 Fortuitous 27 (51%) 174 (13%) 4.4*** (2.4–8.2)
 Screeningb 7 (13%) 614 (46%) 0.3* (0.1–0.8)
Sector of care   
 Private 16 (30%) 784 (59%) 1a
 Public 37 (70%) 546 (41%) 3.3*** (1.8–6.0)
Stage   
 T1  21 (40%) 198 (15%) 1a
 T2  19 (36%) 400 (30%) 0.4* (0.2–0.9)
 T3  7 (13%) 430 (32%) 0.2*** (0.1–0.4)
 T4  0 (–%) 51 (4%) –
 M1 6 (11%) 251 (19%) 0.2** (0.1–0.6)
Lymph nodes   
 Negative 27 (51%) 732 (55%) 1a
 Positive 5 (9%) 145 (11%) 0.9 (0.4–2.5)
 Unknown 21 (40%) 453 (34%) 1.3 (0.7–2.3)
Differentiation   
 Grade 1 18 (34%) 162 (12%) 1a
 Grade 2 10 (19%) 543 (41%) 0.2*** (0.1–0.4)
 Grade 3–4 15 (28%) 439 (33%) 0.3** (0.2–0.6)
 Unknown 10 (19%) 186 (14%) 0.5 (0.2–1.1)
Histology   
 Adenocarcinoma 50 (94%) 1254 (94%) 1a
 Other 3 (6%) 76 (6%) 1.0 (0.3–3.2)
aReference category
bOnly digital rectal examination (DRE) for cases, DRE+PSA for controls
*p<0.05, **p<0.01, ***p<0.001
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Table 3 presents the risk of prostate cancer-specific 
mortality. Figure 1 shows the 5-year cancer-specifi c sur-
vival curve, according to PSA level at diagnosis. Five-year 
survival was slightly higher in patients presenting with 
low PSA values: 86% (95%CI: 76–96%) vs. 78% (95%CI: 
76–80%) (p=0.351) and the risk of prostate cancer-spe-
cifi c mortality associated with PSA values <4 ng/ml was 
slightly lower (HR: 0.6; 95%CI: 0.3–1.2).The prognosis 
was similar for patients with low or elevated PSA levels
(HR: 1.1; 95%CI: 0.6–2.2 after adjusting for factors sig-
nifi cantly related to prognosis in crude Cox models, i.e., 
age, stage, grade and treatment. 
Discussion
This is one of the rare population-based studies that pro-
vides data on frequency and outcome of prostate cancer 
diagnosed with low PSA values in routine care. Prostate 
cancer with low PSA values represented less than 4% of all 
prostate cancers diagnosed in the population. The majority 
of these cancers were discovered fortuitously by pathologi-
cal examination of the prostate after endoscopic resection 
or following symptoms. Compared with cancers diagnosed 
with high PSA levels, tumours with low PSA values were 
more often localised and well differentiated. However, 
nearly 35% of the tumours with low PSA values had ag-
gressive characteristics or had already metastasised at di-
agnosis. Low PSA values were not associated with lowered 
risk of prostate cancer-specifi c mortality. 
The main limitation of our study is the low number of 
patients, because prostate cancer with PSA values <4 ng/
ml at diagnosis is unusual in routine care practice. In fact, 
most previous observational studies reported series of less 
than 60 patients [2, 5, 13, 19, 21–23, 27, 28]. Another 
limitation is that, despite having information on numer-
ous patient and tumour characteristics, we cannot exclude 
bias linked to putative poorer assessment of grade or other 
prognostic factors among patients with low PSA levels. To 
take into account other putative confounders, we adjusted 
for sociodemographic characteristics such as social class, 
civil status, nationality and period of diagnosis, as they 
have been associated with PSA screening, stage at diagno-
sis, treatment and/or prognosis [29–33].
Our aim is not to question the effi cacy of screening or 
optimal cut-off threshold PSA values, but to provide clini-
cians with non-biased information on the signifi cance and 
prognosis of prostate cancer in patients diagnosed with 
“normal” PSA values. 
For patients presenting with PSA levels <4.0 ng/ml, 
prostate cancer is usually investigated only among men 
presenting with symptoms or clinical indications, result-
ing in a prevalence of approximately 2% [9]. However, this 
prevalence is much higher if systematically investigated in 
routine care [2, 3, 5–8].
The main concern is the prognostic signifi cance of this 
type of cancer. Even though few studies showed no differ-
Table 2 Treatment options for prostate cancer and associated odds ratio for low PSA level at diagnosis
 PPSA <4 ng/ml PSA ≥4 ng/ml Crude odds ratio
 N=53 N=1330
 Cases Controls 
Prostatectomy 12 (23%) 407 (31%) 1a
Radiotherapyb 8 (15%) 286 (22%) 0.9 (0.4–2.4)
Watchful waiting 26 (49%) 323 (24%) 2.7** (1.4–5.5)
Hormone therapy 3 (6%) 165 (12%) 0.6 (0.2–2.2)
Otherc 4 (8%) 149 (11%) 0.9 (0.3–2.9)
aReference category
bIncluding 1 man treated with radiotherapy and hormone therapy among men with low PSA, and 125 men treated with radiotherapy and hor-
mone therapy among men with elevated PSA
cAll men with low PSA values had prostatectomy, 2 were also treated with hormone therapy, 2 others had also radiotherapy. All men with el-
evated PSA values had prostatectomy, 80 were also treated with hormone therapy, 32 others had also radiotherapy and 37 others underwent pros-
tatectomy, radiotherapy and hormone therapy
**p<0.01
Table 3 Risk of prostate cancer-specifi c mortality (hazard ratio) according to PSA level at diagnosis
PSA Patients, N=1383 Deaths, N=368 Crude hazard ratio Multiadjusted hazard ratioa
≥4 ng/ml 133 358 1b 1b
<4 ng/ml 53 10 0.6 (0.3–1.2) 1.1 (0.6–2.2)
aAdjusted for age, stage, differentiation and treatment regimens
bReference category
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ence in tumour characteristics among patients with low 
and elevated PSA levels [8, 14, 19], most studies reported 
that patients presenting with low PSA levels more often 
had well differentiated tumours, a Gleason score <7 or 
organ-confi ned disease [2, 12, 13, 16–18, 20–23]. Nev-
ertheless, high-grade cancers are not uncommon in men 
with low PSA values [2–4, 6, 8, 11–13, 15, 17, 18, 21, 23]; 
low PSA values do not exclude aggressive tumour charac-
teristics. We report that 35% of these tumours are poorly 
differentiated. When we consider moderate and high his-
tological grade tumours together, this proportion increases 
to 58%. 
The usefulness of PSA as a marker of disease activ-
ity and its correlation with survival remains controversial 
[34]. Several studies have evaluated if men with low PSA 
levels at diagnosis presented with similar prognosis as men 
with elevated PSA values [10–18, 35–37]. Some studies re-
ported that men presenting with low PSA values had poorer 
outcome [15], some similar outcome [14, 18] and others re-
ported non-signifi cantly better outcome [11, 13] or signifi -
cantly better outcome [12, 16, 17, 23, 28, 35–37]. However, 
results are diffi cult to compare because of differences in 
patient selection, range of PSA values and methods of anal-
yses. Also, some studies considered only biological failure 
[11, 13, 14, 17, 18, 23, 28] or short-term overall survival 
[12] and not prostate cancer-specifi c mortality. Interesting 
results from a large population-based cohort study reported 
that patients presenting with PSA levels <4 ng/ml had the 
best 10-year disease-specifi c survival, but PSA values were 
not an independent prognostic factor in multiadjusted anal-
ysis [10]. However, this analysis considered all PSA values 
<10 ng/ml together and the authors gave no detailed char-
acteristics of tumours with lower PSA values. We found no 
other studies evaluating prostate cancer-specifi c mortality 
between men with “normal” vs. elevated PSA at diagnosis 
in a non-selected population-based setting, adjusting for 
confounders and including treatment options. 
Finally, some data suggested that certain high-grade 
cancers produce less PSA than low-grade cancers [38]. In 
our study, among the six patients presenting with metastat-
ic disease in the low PSA group, all presented with poorly 
differentiated histological adenocarcinoma. Thus for pa-
tients presenting with low PSA values we can exclude nei-
ther prostate cancer nor metastatic disease.
Despite the fact that these cancers are generally lo-
calised and well differentiated tumours, a non-negligible 
proportion of these patients have poorly differentiated or 
metastatic disease. Low PSA level per se is not an indicator 
of good prognosis in terms of survival. Therefore it should 
not infl uence therapeutic decisions.
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Fig. 1 Prostate cancer-specifi c survival according to PSA level at diagnosis
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